Nasdaq
$0.3680▲ 7.45%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $5.6MShares out 15.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 1d agoAfter-hours26.10.24 06:188-KKey event#●●●#●●●
Traws Pharma, Inc.
Traws Pharma has entered into a Common Stock Purchase Agreement with Roth Principal Investments to raise up to $50 million in gross proceeds. The company has the sole discretion to issue and sell newly issued common stock to the investor, who is granted registration rights for the resale of these shares. This financing is intended for general corporate purposes and is subject to limitations, including an Exchange Cap under Nasdaq rules.…more
$0.3680+7.45%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 4d agoAfter-hours26.10.21 05:09DEFA14AOther
Traws Pharma, Inc.
Traws Pharma, Inc. will hold a special meeting on December 3, 2026, to seek shareholder approval for granting the Board authority to effect a reverse stock split at a ratio between 1-for-8 and 1-for-15. Shareholders are required to cast their votes by 11:59 PM ET on December 2, 2026.…more
$0.3680+7.45%vs prev closeView filingShare - 4d agoAfter-hours26.10.21 05:05DEF 14AOther
Traws Pharma, Inc.
Traws Pharma will hold a special meeting of stockholders on December 3, 2026, to vote on granting the Board authority to effect a reverse stock split of its common stock at a ratio between 1-for-8 and 1-for-15. The Board has recommended a vote in favor of this proposal to adjust the number of outstanding shares.…more
$0.3680+7.45%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoAfter-hours26.10.24 06:23Bullish#●●●#●●●#●●●
Traws Pharma Enters $50M Stock Purchase Agreement
Traws Pharma has entered into a stock purchase agreement to sell up to $50 million of common stock to Roth Principal Investments. This capital raising initiative may lead to potential dilution for existing shareholders.…more
$0.3680+7.45%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.14After-hours26.08.15 05:30
●●●●●●●● ●●●●● ●●●●●●
Traws Pharma plans to resubmit toxicology data to the UK's MHRA to resume its influenza program for tivoxavir marboxil. The company has also established a milestone-based financing structure to access up to $50 million in additional capital.…more
$0.3680+7.45%vs prev close
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report